{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:50:35Z","timestamp":1793663435292,"version":"4.5.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s40257-021-00655-y","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T03:02:48Z","timestamp":1642734168000},"page":"13-19","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":112,"title":["Pathophysiology of Generalized Pustular Psoriasis"],"prefix":"10.1007","volume":"23","author":[{"given":"Slaheddine","family":"Marrakchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lluis","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"key":"655_CR1","first-page":"131","volume":"6","author":"KE Benjegerdes","year":"2016","unstructured":"Benjegerdes KE, Hyde K, Kivelevitch D, Mansouri B. Pustular psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016;6:131\u201344.","journal-title":"Psoriasis (Auckl)."},{"key":"655_CR2","unstructured":"Shah M, Al Aboud DM, Crane JS, Kumar S. Pustular psoriasis. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2021, StatPearls Publishing LLC; 2021."},{"issue":"10","key":"655_CR3","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1111\/exd.13699","volume":"27","author":"A Boehner","year":"2018","unstructured":"Boehner A, Navarini AA, Eyerich K. Generalized pustular psoriasis - a model disease for specific targeted immunotherapy, systematic review. Exp Dermatol. 2018;27(10):1067\u201377.","journal-title":"Exp Dermatol"},{"key":"655_CR4","first-page":"37","volume":"9","author":"K Ly","year":"2019","unstructured":"Ly K, Beck KM, Smith MP, Thibodeaux Q, Bhutani T. Diagnosis and screening of patients with generalized pustular psoriasis. Psoriasis (Auckl). 2019;9:37\u201342.","journal-title":"Psoriasis (Auckl)."},{"issue":"12","key":"655_CR5","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1111\/j.1600-0560.2010.01612.x","volume":"37","author":"SH Kardaun","year":"2010","unstructured":"Kardaun SH, Kuiper H, Fidler V, Jonkman MF. The histopathological spectrum of acute generalized exanthematous pustulosis (AGEP) and its differentiation from generalized pustular psoriasis. J Cutan Pathol. 2010;37(12):1220\u20139.","journal-title":"J Cutan Pathol"},{"issue":"11","key":"655_CR6","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1111\/jdv.14386","volume":"31","author":"AA Navarini","year":"2017","unstructured":"Navarini AA, Burden AD, Capon F, Mrowietz U, Puig L, K\u00f6ks S, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31(11):1792\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"655_CR7","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1080\/1744666X.2019.1648209","volume":"15","author":"MJ Gooderham","year":"2019","unstructured":"Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;15(9):907\u201319.","journal-title":"Expert Rev Clin Immunol"},{"issue":"11","key":"655_CR8","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1111\/1346-8138.14523","volume":"45","author":"H Fujita","year":"2018","unstructured":"Fujita H, Terui T, Hayama K, Akiyama M, Ikeda S, Mabuchi T, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP. J Dermatol. 2018;45(11):1235\u201370.","journal-title":"J Dermatol"},{"issue":"2","key":"655_CR9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jaad.2011.01.032","volume":"67","author":"A Robinson","year":"2012","unstructured":"Robinson A, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Bebo BF Jr, et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2012;67(2):279\u201388.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"655_CR10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/1744666X.2019.1708193","volume":"16","author":"S Kharawala","year":"2020","unstructured":"Kharawala S, Golembesky AK, Bohn RL, Esser D. The clinical, humanistic, and economic burden of generalized pustular psoriasis: a structured review. Expert Rev Clin Immunol. 2020;16(3):239\u201352.","journal-title":"Expert Rev Clin Immunol"},{"issue":"6","key":"655_CR11","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/ijd.12070","volume":"53","author":"SE Choon","year":"2014","unstructured":"Choon SE, Lai NM, Mohammad NA, Nanu NM, Tey KE, Chew SF. Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol. 2014;53(6):676\u201384.","journal-title":"Int J Dermatol"},{"issue":"6","key":"655_CR12","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3390\/ijms20061475","volume":"20","author":"A Rendon","year":"2019","unstructured":"Rendon A, Sch\u00e4kel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"655_CR13","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1038\/jid.2012.490","volume":"133","author":"N Setta-Kaffetzi","year":"2013","unstructured":"Setta-Kaffetzi N, Navarini AA, Patel VM, Pullabhatla V, Pink AE, Choon SE, et al. Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes. J Invest Dermatol. 2013;133(5):1366\u20139.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"655_CR14","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.ajhg.2011.07.022","volume":"89","author":"A Onoufriadis","year":"2011","unstructured":"Onoufriadis A, Simpson MA, Pink AE, Di Meglio P, Smith CH, Pullabhatla V, et al. Mutations in IL36RN\/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet. 2011;89(3):432\u20137.","journal-title":"Am J Hum Genet"},{"issue":"6","key":"655_CR15","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/j.jaci.2017.05.019","volume":"140","author":"M Akiyama","year":"2017","unstructured":"Akiyama M, Takeichi T, McGrath JA, Sugiura K. Autoinflammatory keratinization diseases. J Allergy Clin Immunol. 2017;140(6):1545\u20137.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"655_CR16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jaci.2016.08.056","volume":"140","author":"A Johnston","year":"2017","unstructured":"Johnston A, Xing X, Wolterink L, Barnes DH, Yin Z, Reingold L, et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2017;140(1):109\u201320.","journal-title":"J Allergy Clin Immunol"},{"key":"655_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coi.2017.07.007","volume":"49","author":"Y Liang","year":"2017","unstructured":"Liang Y, Sarkar MK, Tsoi LC, Gudjonsson JE. Psoriasis: a mixed autoimmune and autoinflammatory disease. Curr Opin Immunol. 2017;49:1\u20138.","journal-title":"Curr Opin Immunol"},{"issue":"6","key":"655_CR18","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","volume":"201","author":"JE Hawkes","year":"2018","unstructured":"Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 2018;201(6):1605\u201313.","journal-title":"J Immunol"},{"issue":"1","key":"655_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2340\/00015555-2808","volume":"98","author":"K Furue","year":"2018","unstructured":"Furue K, Yamamura K, Tsuji G, Mitoma C, Uchi H, Nakahara T, et al. Highlighting interleukin-36 signalling in plaque psoriasis and pustular psoriasis. Acta Derm Venereol. 2018;98(1):5\u201313.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"655_CR20","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3892\/ijmm.2021.4951","volume":"47","author":"J Zhou","year":"2021","unstructured":"Zhou J, Luo Q, Cheng Y, Wen X, Liu J. An update on genetic basis of generalized pustular psoriasis (review). Int J Mol Med. 2021;47(6):118.","journal-title":"Int J Mol Med"},{"issue":"1","key":"655_CR21","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/imr.12610","volume":"281","author":"EY Bassoy","year":"2018","unstructured":"Bassoy EY, Towne JE, Gabay C. Regulation and function of interleukin-36 cytokines. Immunol Rev. 2018;281(1):169\u201378.","journal-title":"Immunol Rev"},{"issue":"6","key":"655_CR22","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.3390\/ijms20061257","volume":"20","author":"MA Boutet","year":"2019","unstructured":"Boutet MA, Nerviani A, Pitzalis C. IL-36, IL-37, and IL-38 cytokines in skin and joint inflammation: a comprehensive review of their therapeutic potential. Int J Mol Sci. 2019;20(6):1257.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"655_CR23","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.3390\/ijms22094344","volume":"22","author":"H Iznardo","year":"2021","unstructured":"Iznardo H, Puig L. Exploring the role of IL-36 cytokines as a new target in psoriatic disease. Int J Mol Sci. 2021;22(9):4344.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"655_CR24","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41423-020-0519-3","volume":"18","author":"R Uppala","year":"2021","unstructured":"Uppala R, Tsoi LC, Harms PW, Wang B, Billi AC, Maverakis E, et al. \u201cAutoinflammatory psoriasis\u201d-genetics and biology of pustular psoriasis. Cell Mol Immunol. 2021;18(2):307\u201317.","journal-title":"Cell Mol Immunol"},{"issue":"7","key":"655_CR25","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1056\/NEJMoa1013068","volume":"365","author":"S Marrakchi","year":"2011","unstructured":"Marrakchi S, Guigue P, Renshaw BR, Puel A, Pei XY, Fraitag S, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011;365(7):620\u20138.","journal-title":"N Engl J Med"},{"issue":"3","key":"655_CR26","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.jaci.2018.06.038","volume":"143","author":"S Twelves","year":"2019","unstructured":"Twelves S, Mostafa A, Dand N, Burri E, Farkas K, Wilson R, et al. Clinical and genetic differences between pustular psoriasis subtypes. J Allergy Clin Immunol. 2019;143(3):1021\u20136.","journal-title":"J Allergy Clin Immunol"},{"issue":"13","key":"655_CR27","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.3390\/ijms20133318","volume":"20","author":"S Madonna","year":"2019","unstructured":"Madonna S, Girolomoni G, Dinarello CA, Albanesi C. The significance of IL-36 hyperactivation and IL-36R targeting in psoriasis. Int J Mol Sci. 2019;20(13):3318.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"655_CR28","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.jaci.2014.09.043","volume":"135","author":"S Hussain","year":"2015","unstructured":"Hussain S, Berki DM, Choon SE, Burden AD, Allen MH, Arostegui JI, et al. IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis. J Allergy Clin Immunol. 2015;135(4):1067-70.e9.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"655_CR29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00403-015-1611-x","volume":"308","author":"TS Wang","year":"2016","unstructured":"Wang TS, Chiu HY, Hong JB, Chan CC, Lin SJ, Tsai TF. Correlation of IL36RN mutation with different clinical features of pustular psoriasis in Chinese patients. Arch Dermatol Res. 2016;308(1):55\u201363.","journal-title":"Arch Dermatol Res"},{"issue":"11","key":"655_CR30","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1038\/jid.2013.230","volume":"133","author":"K Sugiura","year":"2013","unstructured":"Sugiura K, Takemoto A, Yamaguchi M, Takahashi H, Shoda Y, Mitsuma T, et al. The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist. J Invest Dermatol. 2013;133(11):2514\u201321.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"655_CR31","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/bjd.15867","volume":"178","author":"R M\u00f6ssner","year":"2018","unstructured":"M\u00f6ssner R, Wilsmann-Theis D, Oji V, Gkogkolou P, L\u00f6hr S, Schulz P, et al. The genetic basis for most patients with pustular skin disease remains elusive. Br J Dermatol. 2018;178(3):740\u20138.","journal-title":"Br J Dermatol"},{"key":"655_CR32","doi-asserted-by":"crossref","unstructured":"Sugiura K, Muto M, Akiyama M. CARD14 c.526G>C (p.Asp176His) is a significant risk factor for generalized pustular psoriasis with psoriasis vulgaris in the Japanese cohort. J Invest Dermatol. 2014;134(6):1755\u20137.","DOI":"10.1038\/jid.2014.46"},{"issue":"2","key":"655_CR33","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/bjd.17392","volume":"180","author":"L Li","year":"2019","unstructured":"Li L, You J, Fu X, Wang Z, Sun Y, Liu H, et al. Variants of CARD14 are predisposing factors for generalized pustular psoriasis (GPP) with psoriasis vulgaris but not for GPP alone in a Chinese population. Br J Dermatol. 2019;180(2):425\u20136.","journal-title":"Br J Dermatol"},{"issue":"5","key":"655_CR34","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.ajhg.2014.04.005","volume":"94","author":"N Setta-Kaffetzi","year":"2014","unstructured":"Setta-Kaffetzi N, Simpson MA, Navarini AA, Patel VM, Lu H-C, Allen MH, et al. AP1S3 mutations are associated with pustular psoriasis and impaired Toll-like receptor 3 trafficking. Am J Hum Genet. 2014;94(5):790\u20137.","journal-title":"Am J Hum Genet"},{"issue":"11","key":"655_CR35","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1016\/j.jid.2016.06.618","volume":"136","author":"SK Mahil","year":"2016","unstructured":"Mahil SK, Twelves S, Farkas K, Setta-Kaffetzi N, Burden AD, Gach JE, et al. AP1S3 mutations cause skin autoinflammation by disrupting keratinocyte autophagy and up-regulating IL-36 production. J Invest Dermatol. 2016;136(11):2251\u20139.","journal-title":"J Invest Dermatol"},{"issue":"7","key":"655_CR36","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/j.jid.2019.11.024","volume":"140","author":"S Frey","year":"2020","unstructured":"Frey S, Sticht H, Wilsmann-Theis D, Gersch\u00fctz A, Wolf K, L\u00f6hr S, et al. Rare loss-of-function mutation in SERPINA3 in generalized pustular psoriasis. J Invest Dermatol. 2020;140(7):1451-5.e13.","journal-title":"J Invest Dermatol"},{"issue":"13","key":"655_CR37","doi-asserted-by":"publisher","first-page":"E2748","DOI":"10.1073\/pnas.1620954114","volume":"114","author":"JS Ainscough","year":"2017","unstructured":"Ainscough JS, Macleod T, McGonagle D, Brakefield R, Baron JM, Alase A, et al. Cathepsin S is the major activator of the psoriasis-associated proinflammatory cytokine IL-36\u03b3. Proc Natl Acad Sci U S A. 2017;114(13):E2748\u201357.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"655_CR38","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.ajhg.2020.06.020","volume":"107","author":"M Vergnano","year":"2020","unstructured":"Vergnano M, Mockenhaupt M, Benzian-Olsson N, Paulmann M, Grys K, Mahil SK, et al. Loss-of-function myeloperoxidase mutations are associated with increased neutrophil counts and pustular skin disease. Am J Hum Genet. 2020;107(3):539\u201343.","journal-title":"Am J Hum Genet"},{"issue":"3","key":"655_CR39","doi-asserted-by":"publisher","first-page":"e043666","DOI":"10.1136\/bmjopen-2020-043666","volume":"11","author":"SE Choon","year":"2021","unstructured":"Choon SE, Lebwohl MG, Marrakchi S, Burden AD, Tsai TF, Morita A, et al. Study protocol of the global EffisayilTM 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare. BMJ Open. 2021;11(3):e043666.","journal-title":"BMJ Open"},{"issue":"7","key":"655_CR40","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/1346-8138.14318","volume":"45","author":"D Wilsmann-Theis","year":"2018","unstructured":"Wilsmann-Theis D, Schnell LM, Ralser-Isselstein V, Bieber T, Sch\u00f6n MP, H\u00fcffmeier U, et al. Successful treatment with interleukin-17A antagonists of generalized pustular psoriasis in patients without IL36RN mutations. J Dermatol. 2018;45(7):850\u20134.","journal-title":"J Dermatol"},{"issue":"9","key":"655_CR41","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/1346-8138.13306","volume":"43","author":"S Imafuku","year":"2016","unstructured":"Imafuku S, Honma M, Okubo Y, Komine M, Ohtsuki M, Morita A, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol. 2016;43(9):1011\u20137.","journal-title":"J Dermatol"},{"key":"655_CR42","doi-asserted-by":"crossref","unstructured":"Kromer C, Loewe E, Schaarschmidt ML, Pinter A, Gerdes S, Herr R, et al. Drug survival in the treatment of generalized pustular psoriasis: a retrospective multicenter study. Dermatol Ther. 2021;34(2):e14814.","DOI":"10.1111\/dth.14814"},{"issue":"6","key":"655_CR43","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1111\/jdv.12773","volume":"29","author":"H Saeki","year":"2015","unstructured":"Saeki H, Nakagawa H, Ishii T, Morisaki Y, Aoki T, Berclaz PY, et al. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatol Venereol. 2015;29(6):1148\u201355.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"655_CR44","doi-asserted-by":"publisher","first-page":"e400","DOI":"10.1111\/ijd.14959","volume":"59","author":"R Taguchi","year":"2020","unstructured":"Taguchi R, Takamura S, Teraki Y. Combination therapy with biologic and colchicine for generalized pustular psoriasis. Int J Dermatol. 2020;59(11):e400\u20132.","journal-title":"Int J Dermatol"},{"issue":"5","key":"655_CR45","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/1346-8138.14294","volume":"45","author":"S Sano","year":"2018","unstructured":"Sano S, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study. J Dermatol. 2018;45(5):529\u201339.","journal-title":"J Dermatol"},{"issue":"5","key":"655_CR46","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40262-019-00829-2","volume":"59","author":"AA Suleiman","year":"2020","unstructured":"Suleiman AA, Khatri A, Oberoi RK, Othman AA. Exposure-response relationships for the efficacy and safety of risankizumab in Japanese subjects with psoriasis. Clin Pharmacokinet. 2020;59(5):575\u201389.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"655_CR47","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/bjd.14702","volume":"176","author":"KN Yamasaki","year":"2017","unstructured":"Yamasaki KN, Kubo H, Ootaki Y. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol. 2017;176(3):741\u201351.","journal-title":"Br J Dermatol"},{"issue":"2","key":"655_CR48","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/1346-8138.13047","volume":"43","author":"H Kawakami","year":"2016","unstructured":"Kawakami H, Matsumoto Y, Abe N, Katori Y, Takahashi K, Tsuboi R, et al. Perioperative management of tumor necrosis factor-alpha blocker-treated psoriatic patients: case reports and review. J Dermatol. 2016;43(2):190\u20133.","journal-title":"J Dermatol"},{"issue":"2","key":"655_CR49","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/1346-8138.13632","volume":"44","author":"A Matsumoto","year":"2017","unstructured":"Matsumoto A, Komine M, Karakawa M, Kishimoto M, Ohtsuki M. Adalimumab administration after infliximab therapy is a successful treatment strategy for generalized pustular psoriasis. J Dermatol. 2017;44(2):202\u20134.","journal-title":"J Dermatol"},{"issue":"12","key":"655_CR50","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1111\/1346-8138.13429","volume":"43","author":"A Adachi","year":"2016","unstructured":"Adachi A, Komine M, Hirano T, Tsuda H, Karakawa M, Murata S, et al. Case of generalized pustular psoriasis exacerbated during pregnancy, successfully treated with infliximab. J Dermatol. 2016;43(12):1439\u201340.","journal-title":"J Dermatol"},{"issue":"10","key":"655_CR51","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1111\/jdv.12590","volume":"29","author":"K Sugiura","year":"2015","unstructured":"Sugiura K, Endo K, Akasaka T, Akiyama M. Successful treatment with infliximab of sibling cases with generalized pustular psoriasis caused by deficiency of interleukin-36 receptor antagonist. J Eur Acad Dermatol Venereol. 2015;29(10):2054\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"655_CR52","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1001\/2013.jamadermatol.80","volume":"148","author":"M Viguier","year":"2012","unstructured":"Viguier M, Aubin F, Delaporte E, Pag\u00e8s C, Paul C, Beylot-Barry M, et al. Efficacy and safety of tumor necrosis factor inhibitors in acute generalized pustular psoriasis. Arch Dermatol. 2012;148(12):1423\u20135.","journal-title":"Arch Dermatol"},{"key":"655_CR53","unstructured":"A study to evaluate the efficacy and safety of anb019 in subjects with generalized pustular psoriasis. https:\/\/ClinicalTrials.gov\/show\/NCT03619902."},{"issue":"10","key":"655_CR54","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMc1811317","volume":"380","author":"H Bachelez","year":"2019","unstructured":"Bachelez H, Choon SE, Marrakchi S, Burden AD, Tsai TF, Morita A, et al. Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis. N Engl J Med. 2019;380(10):981\u20133.","journal-title":"N Engl J Med"},{"key":"655_CR55","unstructured":"A study to test whether BI 655130 (spesolimab) prevents flare-ups in patients with generalized pustular psoriasis. https:\/\/ClinicalTrials.gov\/show\/NCT04399837."},{"key":"655_CR56","unstructured":"A study to evaluate the efficacy and safety of ANB019 in subjects with palmoplantar pustulosis. https:\/\/ClinicalTrials.gov\/show\/NCT03633396."},{"key":"655_CR57","unstructured":"A study to test long-term treatment with spesolimab in people with palmoplantar pustulosis (PPP) who took part in previous studies with spesolimab. https:\/\/ClinicalTrials.gov\/show\/NCT04493424."},{"issue":"1","key":"655_CR58","doi-asserted-by":"publisher","first-page":"9089","DOI":"10.1038\/s41598-019-45626-w","volume":"9","author":"V Todorovi\u0107","year":"2019","unstructured":"Todorovi\u0107 V, Su Z, Putman CB, Kakavas SJ, Salte KM, McDonald HA, et al. Small molecule IL-36\u03b3 antagonist as a novel therapeutic approach for plaque psoriasis. Sci Rep. 2019;9(1):9089.","journal-title":"Sci Rep"},{"issue":"4","key":"655_CR59","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1093\/rheumatology\/kez358","volume":"59","author":"MA Boutet","year":"2020","unstructured":"Boutet MA, Nerviani A, Lliso-Ribera G, Lucchesi D, Prediletto E, Ghirardi GM, et al. Interleukin-36 family dysregulation drives joint inflammation and therapy response in psoriatic arthritis. Rheumatology (Oxford). 2020;59(4):828\u201338.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"655_CR60","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/bjd.13614","volume":"173","author":"B Mansouri","year":"2015","unstructured":"Mansouri B, Richards L, Menter A. Treatment of two patients with generalized pustular psoriasis with the interleukin-1\u03b2 inhibitor gevokizumab. Br J Dermatol. 2015;173(1):239\u201341.","journal-title":"Br J Dermatol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-021-00655-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-021-00655-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-021-00655-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T04:27:49Z","timestamp":1666585669000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-021-00655-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":60,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["655"],"URL":"https:\/\/doi.org\/10.1007\/s40257-021-00655-y","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"26 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article has been published as part of a journal supplement wholly funded by Boehringer Ingelheim.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure statement"}},{"value":"Medical writing support was funded by Boehringer Ingelheim.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Lluis Puig has received honoraria or fees for serving on advisory boards, as a speaker, and as a consultant, as well as grants as an investigator from AbbVie, Almirall, Amgen, Baxalta, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius-Kabi, Janssen, JS BIOCAD, LEO Pharma, Lilly, Mylan, Novartis, Pfizer, Regeneron, Roche, Sandoz, Samsung-Bioepis, Sanofi, and UCB. Slaheddine Marrakchi has received consulting fees from Boehringer Ingelheim.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"The sponsor of the supplement and all authors identified and discussed the concept for each chapter and the supplement as a whole; further development of each review article was at the direction of the authors who provided guidance to OPEN Health on the content of the article, critically revised the work, and approved the content for publication.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}